Increased antimicrobial resistance during the COVID-19 pandemic.
Int J Antimicrob Agents
; 57(4): 106324, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1141886
ABSTRACT
In addition to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection itself, an increase in the incidence of antimicrobial resistance poses collateral damage to the current status of the COVID-19 (coronavirus disease 2019) pandemic. There has been a rapid increase in multidrug-resistant organisms (MDROs), including extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae, carbapenem-resistant New Delhi metallo-ß-lactamase (NDM)-producing Enterobacterales, Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus (MRSA), pan-echinocandin-resistant Candida glabrata and multi-triazole-resistant Aspergillus fumigatus. The cause is multifactorial and is particularly related to high rates of antimicrobial agent utilisation in COVID-19 patients with a relatively low rate of co- or secondary infection. Appropriate prescription and optimised use of antimicrobials according to the principles of antimicrobial stewardship as well as quality diagnosis and aggressive infection control measures may help prevent the occurrence of MDROs during this pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Bacterial Infections
/
Drug Resistance, Microbial
/
Coinfection
/
COVID-19
/
Anti-Bacterial Agents
/
Mycoses
Type of study:
Observational study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Int J Antimicrob Agents
Year:
2021
Document Type:
Article
Affiliation country:
J.ijantimicag.2021.106324
Similar
MEDLINE
...
LILACS
LIS